Drugs / autologous lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00138229 | Jul 2005 → Apr 2007 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00138229 ↗ |
| Modality | Cell therapy | “Autologous CD25-positive-T-regulatory-cell-depleted lymphocyte reinfusion” NCT00138229 ↗ |
| Route | Intravenous | “Patients receive autologous lymphocytes IV over 20-30 minutes on day 0” NCT00138229 ↗ |